RARX Ra Pharmaceuticals Inc.

33.68
+0.5  (+2%)
Previous Close 33.18
Open 33.2
Price To Book 7.45
Market Cap 1,424,820,452
Shares 42,303,138
Volume 24,499
Short Ratio
Av. Daily Volume 469,096

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 trial to commence 2H 2019.
RA101495 zilucoplan
Myasthenia Gravis (MG)
Phase 1b PK data released September 26, 2018.
RA101495 SC
Atypical hemolytic uremic syndrome (aHUS)

Latest News

  1. Ra Pharmaceuticals and Camurus Announce Exclusive License Agreement for FluidCrystal® Extended Release Formulation of Zilucoplan
  2. Ra Pharmaceuticals Announces Expansion of Neuromuscular Portfolio with Clearance of IND Application for Zilucoplan for the Treatment of Immune-Mediated Necrotizing Myopathy
  3. Ra Pharmaceuticals to Present at Upcoming Investor Conferences
  4. Hedge Funds Have Never Been This Bullish On Ra Pharmaceuticals, Inc. (RARX)
  5. Ra Pharmaceuticals Reports First Quarter 2019 Financial Results and Provides Corporate Update
  6. Ra Pharmaceuticals Announces Positive gMG Phase 2 and Open-Label, Long-Term Extension Data at the 2019 AAN Annual Meeting
  7. Ra Pharmaceuticals Presents Pre-Clinical Data for Zilucoplan XR at the 6th Annual Peptides Congress
  8. Ra Pharmaceuticals Closes End-of-Phase 2 Interaction with FDA
  9. Ra Pharmaceuticals Announces Completion of End-of-Phase 2 Interactions with FDA and Design of Pivotal Phase 3 gMG Study
  10. Ra Pharmaceuticals Announces Acceptance of gMG Phase 2 and Open-Label, Long-Term Extension Data for Emerging Science Dual Presentation at the 2019 AAN Annual Meeting
  11. Ra Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Corporate Update
  12. Ra Pharmaceuticals to Present at the Cowen 39th Annual Health Care Conference
  13. Ra Pharmaceuticals Supports 12th Annual Rare Disease Day® and Joins Global Movement to Raise Awareness for Rare Diseases
  14. 5 Clinical-Stage Biotech Stocks to Buy
  15. Ra Pharmaceuticals to Present at the 8th Annual SVB Leerink Global Healthcare Conference
  16. Hedge Funds Are Betting On Ra Pharmaceuticals, Inc. (RARX)
  17. Ra Pharmaceuticals Announces Pricing of Public Offering of Common Stock
  18. The Daily Biotech Pulse: Management Change At Merck, Jazz Buyback, Arrowhead Earnings
  19. Why Nutrisystem, Xperi, and Ra Pharmaceuticals Jumped Today